Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
33.56
-1.42 (-4.06%)
At close: Oct 10, 2025, 4:00 PM EDT
33.16
-0.40 (-1.19%)
After-hours: Oct 10, 2025, 7:59 PM EDT
Viking Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts that cover Viking Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $86.42, which forecasts a 157.51% increase in the stock price over the next year. The lowest target is $30 and the highest is $125.
Price Target: $86.42 (+157.51%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Viking Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 6 |
| Buy | 6 | 6 | 6 | 6 | 6 | 4 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 13 | 13 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $102 | Strong Buy | Reiterates | $102 | +203.93% | Sep 29, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $125 | Strong Buy | Reiterates | $125 | +272.47% | Sep 22, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $102 | Strong Buy | Reiterates | $102 | +203.93% | Aug 19, 2025 |
| Raymond James | Raymond James | Strong Buy Maintains $125 → $122 | Strong Buy | Maintains | $125 → $122 | +263.53% | Jul 24, 2025 |
| Citigroup | Citigroup | Hold Maintains $31 → $38 | Hold | Maintains | $31 → $38 | +13.23% | Jul 24, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
6.79M
EPS This Year
-2.47
from -1.01
EPS Next Year
-3.19
from -2.47
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 97.9M | |||
| Avg | n/a | 6.8M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.95 | -2.34 | |||
| Avg | -2.47 | -3.19 | |||
| Low | -2.67 | -4.26 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.